Promore: Mixed Study Data
Research Note
2020-11-20
08:45
Redeye is reviewing its fair value range with a negative bias following what we regard as mixed trial data, from Promore Pharma’s phase 2b “HEAL” LL 37 study on venous leg ulcers, pending more data transparency and strategy response considerations.
FT
LS
Fredrik Thor
Ludvig Svensson
Disclosures and disclaimers